510(k) · Cleared
ClearedLzi Oxycodone Homogeneous Enzyme Immunoassay, Lzi Oxycondone Calibrators, Lzi Oxycodone Controls
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Lin-Zhi International, Inc. · DJG Enzyme Immunoassay, Opiates
Cleared on Jun 1, 2012 as substantially equivalent to K050733 (Lin-Zhi International, Inc., 2005) after an 80-day review. Its family tree reaches back 3 generations to 2002. 5 later devices descend from it.
- Decided
- Jun 1, 2012
- Review
- 80 days
- Class
- Class II
- Product code
- DJG
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 3 generations to K014101 (2002). 5 later devices descend from it, 2 citing it directly.
- Root · 3 generations backK014101 Rapidone-Oxy TestAmerican Bio Medica Corp. · 2002
- 2 generations backK040411 Dri Oxycodone AssayMicrogenics Corp. · 2004
- 1 generation backK050733 Oxycodone Enzyme Immunoassay and Oxycodone Calibrators and ControlsLin-Zhi International, Inc. · 2005
- This deviceK120763 Lzi Oxycodone Homogeneous Enzyme Immunoassay, Lzi Oxycondone…Lin-Zhi International, Inc. · 2012
- Descendant · cites it directly · 3 of its ownK141055 Lzi Hydrocodone; Enzyme Immunoassay, Calibrators; (5ML), (15ML)…Lin-Zhi International, Inc. · 2014
- Descendant · 2 generations on · 2 of its ownK150502 DRI Hydrocodone Assay, DRI Hydrocodone Calibrators, DRI Hydrocodone…Microgenics Corporation · 2015
- Descendant · 3 generations on · 0 of its ownK231752 ARK Hydrocodone AssayArk Diagnostics, Inc. · 2023
- Descendant · cites it directly · 0 of its ownK202007 LZI Oxycodone III Enzyme ImmunoassayLin-Zhi International, Inc. · 2020
- Descendant · 3 generations on · 0 of its ownK173195 DRI Hydrocodone AssayMicrogenics Corporation · 2018
Most influential descendants
Showing 5 of 5 · See all- K141055Lzi Hydrocodone; Enzyme Immunoassay, Calibrators; (5ML), (15ML); Controls; (5ML), (15ML)Lin-Zhi International, Inc. · 2014 · cites it directly3descendants
- K150502DRI Hydrocodone Assay, DRI Hydrocodone Calibrators, DRI Hydrocodone ControlsMicrogenics Corporation · 2015 · 2 generations on2descendants
- K231752ARK Hydrocodone AssayArk Diagnostics, Inc. · 2023 · 3 generations on0descendants
- K202007LZI Oxycodone III Enzyme ImmunoassayLin-Zhi International, Inc. · 2020 · cites it directly0descendants
- K173195DRI Hydrocodone AssayMicrogenics Corporation · 2018 · 3 generations on0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −3 | K014101 | Rapidone-Oxy Test | American Bio Medica Corp. | 2002 | — |
| −2 | K040411 | Dri Oxycodone Assay | Microgenics Corp. | 2004 | — |
| −1 | K050733 | Oxycodone Enzyme Immunoassay and Oxycodone Calibrators and Controls | Lin-Zhi International, Inc. | 2005 | — |
| 0 (this device) | K120763 | Lzi Oxycodone Homogeneous Enzyme Immunoassay, Lzi Oxycondone Calibrators, Lzi… | Lin-Zhi International, Inc. | 2012 | — |
| +1 | K141055 | Lzi Hydrocodone; Enzyme Immunoassay, Calibrators; (5ML), (15ML); Controls… | Lin-Zhi International, Inc. | 2014 | — |
| +2 | K150502 | DRI Hydrocodone Assay, DRI Hydrocodone Calibrators, DRI Hydrocodone Controls | Microgenics Corporation | 2015 | — |
| +3 | K231752 | ARK Hydrocodone Assay | Ark Diagnostics, Inc. | 2023 | — |
| +1 | K202007 | LZI Oxycodone III Enzyme Immunoassay | Lin-Zhi International, Inc. | 2020 | — |
| +3 | K173195 | DRI Hydrocodone Assay | Microgenics Corporation | 2018 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2014 | 1 | 0 |
| 2015 | 1 | 0 |
| 2018 | 1 | 0 |
| 2020 | 1 | 0 |
| 2023 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in DJG? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new DJG device
- #1 K232659 Dochek® Multi-Drug Urine Test Cup Rx, Dochek®…score 17.6 · 8 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K050733 | Oxycodone Enzyme Immunoassay and Oxycodone Calibrators and ControlsSummary page 2…lly Marketed Predicate Device(s) The LZI Oxycodone Enzyme Immunoassay (ELA) is substantially equivalent to the Lin-Zhi International, Inc. Oxycodone Enzyme Immunoassay (k050733) manufactured by Lin-Zhi International, Inc. The LZI Oxycodone Enzyme Immunoassay is identical or similar to its predicate in ter… | 2005 |
What descends from it? (5)
2 later devices cite it directly; ranked here by how many devices descend from each in turn.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 10 years and passes through 3 companies; a new generation was cleared every 2.2 years on median.
- None of the 3 ancestors has a recall.
- Of its descendants, K141055 (Lin-Zhi International, Inc., 2014) has gone furthest, with 3 descendants of its own.
How does its category compare?
All DJG devicesDJG Enzyme Immunoassay, Opiates: FDA decisions, review times, recalls and adverse event reports over 20 years. 2012, this device’s year, is highlighted.
FDA decisions per year · DJG
3in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · DJG
31in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · DJG
2in 2025
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · DJG
1in 2025
MAUDE reports naming product code DJG, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 2 | — | 0 | 0 |
| 2008 | 2 | — | 0 | 0 |
| 2009 | 2 | — | 0 | 0 |
| 2010 | 6 | 187 | 0 | 0 |
| 2011 | 6 | 233 | 1 | 4 |
| 2012 | 5 | 95 | 0 | 1 |
| 2013 | 5 | 60 | 0 | 4 |
| 2014 | 9 | 62 | 0 | 0 |
| 2015 | 12 | 141 | 0 | 3 |
| 2016 | 2 | — | 0 | 2 |
| 2017 | 4 | 101 | 0 | 1 |
| 2018 | 5 | 134 | 0 | 1 |
| 2019 | 3 | 235 | 1 | 0 |
| 2020 | 5 | 30 | 0 | 0 |
| 2021 | 3 | 422 | 0 | 2 |
| 2022 | 2 | — | 0 | 1 |
| 2023 | 10 | 140 | 0 | 0 |
| 2024 | 5 | 150 | 0 | 3 |
| 2025 | 3 | 31 | 2 | 1 |
| 2026 | 3 | 157 | 0 | — |
What is it indicated for?
The LZI Oxycodone Enzyme Immunoassay is intended for the qualitative and semi- quantitative determination of Oxycodone in human urine at the cutoff values of 100 and 300 nglmL. The assay is designed for professional use with a number of automated clinical chemistry analyzers. The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GCMS…
Read the full statement (193 words)
The LZI Oxycodone Enzyme Immunoassay is intended for the qualitative and semi-
quantitative determination of Oxycodone in human urine at the cutoff values of 100 and 300
nglmL. The assay is designed for professional use with a number of automated clinical
chemistry analyzers.
The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an
appropriate dilution of the specimen for confirmation by a confirmatory method such as
GCMS and LCMS or (2) permitting laboratories to establish quality control procedures.
The LZJ Oxycodone Drugs of Abuse (DAU) Calibrators are for use as calibrators in the
qualitative and semi-quantitative calibration of the LZI Oxycodone Enzyme Immunoassay.
The LZI Oxycodone Drugs of Abuse (DAU) Controls are for use as assayed quality control
materials to monitor the precision of the LZI Oxycodone Enzyme Immunoassay.
The assay provides only a preliminary analytical result A more specific alternative
chemical method must be used in order to obtain a confirmed analytical result. Gas or
liquid chromatography/mass spectrometry (GC/MS or LC/MS) is the preferred
confirmatory method. Clinical consideration and professional judgment should be
exercised with any drug of abuse test result, particularly when the preliminary test result is
positive.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K120763 · printed Nov 5, 2026
Cite this page
510(k) Report. “K120763: Lzi Oxycodone Homogeneous Enzyme Immunoassay, Lzi Oxycondone Calibrators, Lzi Oxycodone Controls.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K120763
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026